- Conditions
- Infantile Hemangiomas
- Interventions
- Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Month to 8 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemangioma
- Interventions
- Prednisolone
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Hemangioma
- Interventions
- timolol maleate 0.5% gel
- Drug
- Lead sponsor
- Rady Children's Hospital, San Diego
- Other
- Eligibility
- 7 Days to 6 Months
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hemangioma, Vascular Anomalies
- Interventions
- Cheek cell samples or blood sample (4mL), Cheek cell sample or blood sample (4mL)
- Genetic
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Hemangioma of Infancy
- Interventions
- propranolol, Prednisolone
- Drug
- Lead sponsor
- Nancy Bauman
- Other
- Eligibility
- 2 Weeks to 6 Months
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Infantile Hemangioma
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 7 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hemangioma
- Interventions
- Prednisolone (Corticosteroid), Propranolol, Placebo
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 9 Months
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hemangioma, Infant
- Interventions
- topical 0.5% Timolol, Control (placebo) group
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 1 Month to 8 Months
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hemangioma
- Interventions
- Not listed
- Lead sponsor
- Rady Children's Hospital, San Diego
- Other
- Eligibility
- Female only
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hemangioma
- Interventions
- Vincristine, Prednisone
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Infantile Hemangioma
- Interventions
- 0.25% Timolol Maleate Gel Forming Solution, 0.5% Timolol Maleate Gel Forming Solution
- Drug
- Lead sponsor
- Kanecia Obie Zimmerman
- Other
- Eligibility
- Up to 84 Days
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 9 more
- Conditions
- Hemangioma Skin
- Interventions
- 5% simvastatin ointment
- Drug
- Lead sponsor
- Joyce Teng
- Other
- Eligibility
- 3 Months to 5 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Infantile Hemangioma, Very Low Birth Weight Infants
- Interventions
- topical 0.5% Timolol maleate, Control (placebo) group
- Drug
- Lead sponsor
- Alice K. Gong
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hemangiomas of Infancy
- Interventions
- No intervention
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 3 Months to 5 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- San Francisco, California • Rochester, Minnesota
- Conditions
- Infantile Hemangioma
- Interventions
- Propranolol three times a day, Propranolol twice a day, Timolol
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Up to 18 Months
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Infantile Hemangiomas
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Month to 5 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Hemangioma
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 1 Year
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Hemangioma
- Interventions
- topical timolol maleate, Pulsed dye laser
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Up to 3 Months
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Infantile Hemangioma
- Interventions
- Propranolol, Placebo
- Drug
- Lead sponsor
- Pierre Fabre Dermatology
- Industry
- Eligibility
- 35 Days to 150 Days
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 10
- States / cities
- Irvine, California • Redwood City, California • San Diego, California + 7 more
- Conditions
- Hemangioma
- Interventions
- abdominal ultrasound, Dermatologic Examination
- Procedure · Other
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri